Top 5 Takeaways Influenza A(H3N2) virus, specifically clade 3C.2a1b.2a.2, emerged in Chile much earlier than in pre-pandemic seasons, resulting in 1,002 hospitalizations in 2022. The influenza vaccination was found to
Blog
Top 5 Takeaways Wastewater Testing Identified PV2 in New York: Wastewater testing in New York detected poliovirus type 2 (PV2), genetically related to the virus from a paralytic polio case
Top 5 Takeaways High Volume of Prescriptions: In 2021, 6.5 million topical antifungal prescriptions, costing $231 million, were filled for Medicare Part D beneficiaries, equating to approximately one prescription for
Top 5 Takeaways New and Updated Vaccine Recommendations: The 2024 immunization schedule includes key changes, notably for influenza, pneumococcal vaccines, RSV monoclonal antibody (RSV-mAb), respiratory syncytial virus vaccines (RSV), COVID-19
Top 5 Takeaways New and Updated Vaccine Recommendations: The 2024 schedule includes changes for respiratory syncytial virus (RSV), influenza, COVID-19, inactivated poliovirus vaccine (IPV), Mpox vaccine, and meningococcal vaccines. Removal
Top 5 Takeaways Bivalent mRNA COVID-19 Vaccine Effectiveness: The bivalent mRNA COVID-19 vaccine was found to be 47% effective in preventing thromboembolic events in immunocompetent persons aged ≥65 years and
Top 5 Takeaways Among 57 patients hospitalized for severe monkeypox during the study period, most were Black men with AIDS, highlighting the severe impact of monkeypox in immunocompromised individuals. Twelve
Top 5 Takeaways Prevalence and Demographics: Monkeypox virus (MPXV) infections in children and adolescents aged <18 years constituted only 0.3% of all U.S. cases during the study period, with no
Top 5 Takeaways Global Decline in Routine Vaccinations: The estimated global coverage for key vaccines, including the three-dose diphtheria-tetanus-pertussis vaccine (DTPcv3) and the first dose of the measles-containing vaccine (MCV1),
Top 5 Takeaways: Safety Profile Similar to Monovalent Boosters: Early safety findings for bivalent COVID-19 mRNA booster doses in persons aged ≥12 years are consistent with those reported for monovalent